Literature DB >> 10665504

Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients.

T Strunk1, S Bubel, B Mascher, P Schlenke, H Kirchner, K P Wandinger.   

Abstract

To determine the frequency of in vivo activated T(H)1 lymphocytes, T-cell subsets of 9 multiple sclerosis patients with active disease and 17 healthy controls were analyzed by immunostaining for CCR5, CD26, and their expression of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. The numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-producing T cells were significantly increased in the peripheral blood of multiple sclerosis patients. CCR5 expression may be a useful marker to identify effector cells in multiple sclerosis and could be used as a tool for monitoring disease activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Authors:  Pia Kivisäkk; Corinna Trebst; Jar-Chi Lee; Barbara H Tucky; Richard A Rudick; James J Campbell; Richard M Ransohoff
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

Review 3.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

4.  CCR5 expression on monocytes and T cells: modulation by transmigration across the blood-brain barrier in vitro.

Authors:  Eroboghene E Ubogu; Melissa K Callahan; Barbara H Tucky; Richard M Ransohoff
Journal:  Cell Immunol       Date:  2007-01-25       Impact factor: 4.868

5.  Functional expression of chemokine receptor CCR5 on CD4(+) T cells during virus-induced central nervous system disease.

Authors:  William G Glass; Thomas E Lane
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 7.  Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Authors:  Laurine Legroux; Nathalie Arbour
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

8.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

9.  CD4+CD28- costimulation-independent T cells in multiple sclerosis.

Authors:  S Markovic-Plese; I Cortese; K P Wandinger; H F McFarland; R Martin
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

10.  CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population.

Authors:  Majid Shahbazi; Hamid Ebadi; Davood Fathi; Danial Roshandel; Mana Mahamadhoseeni; Azam Rashidbaghan; Narges Mahammadi; Mahammad Reza Mahammadi; Mahdi Zamani
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.